Get the Stockscreener App
14.65
6.15%
-0.96
After Hours:
14.93
0.28
+1.91%
Mineralys Therapeutics Inc stock is traded at $14.65, with a volume of 644.84K.
It is down -6.15% in the last 24 hours and up +14.19% over the past month.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
See More
Previous Close:
$15.61
Open:
$15.59
24h Volume:
644.84K
Relative Volume:
0.57
Market Cap:
$1.00B
Revenue:
-
Net Income/Loss:
$-119.67M
P/E Ratio:
-5.3663
EPS:
-2.73
Net Cash Flow:
$-97.30M
1W Performance:
-4.99%
1M Performance:
+14.19%
6M Performance:
+4.34%
1Y Performance:
+2.66%
1-Day Range:
$14.40
$15.94
1-Week Range:
$14.03
$15.94
52-Week Range:
$8.241
$18.38
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
Name
Mineralys Therapeutics Inc
Sector
Industry
Phone
(888) 378-6240
Address
150 N. RADNOR CHESTER ROAD, RADNOR
Compare MLYS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
14.65 | 1.00B | 0 | -119.67M | -97.30M | -2.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-24 | Initiated | H.C. Wainwright | Buy |
| Apr-02-24 | Initiated | Goldman | Buy |
| Mar-07-23 | Initiated | BofA Securities | Buy |
| Mar-07-23 | Initiated | Credit Suisse | Outperform |
| Mar-07-23 | Initiated | Evercore ISI | Outperform |
| Mar-07-23 | Initiated | Guggenheim | Buy |
| Mar-07-23 | Initiated | Stifel | Buy |
| Mar-07-23 | Initiated | Wells Fargo | Overweight |
View All
Mineralys Therapeutics Inc Stock (MLYS) Latest News
Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference - GlobeNewswire
Mineralys Therapeutics Inc expected to post a loss of 98 cents a shareEarnings Preview - TradingView
Mineralys Therapeutics to Announce First Quarter 2025 Financial Results on May 12 - Nasdaq
Mineralys Therapeutics to Announce First Quarter 2025 - GlobeNewswire
Clinical-Stage Biotech Mineralys Therapeutics Sets Q1 Earnings Date: Key Updates on Hypertension Pipeline Expected - Stock Titan
Trend Tracker for (MLYS) - news.stocktradersdaily.com
Mineralys Therapeutics Publishes Pivotal Hypertension Trial Results in NEJM - MSN
Mineralys Therapeutics Inc [MLYS] Records 50-Day SMA of $12.99 - knoxdaily.com
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Shares Bought by Renaissance Technologies LLC - Defense World
Director Makes Bold Move with Multi-Million Dollar Stock Purchase! - TipRanks
March sees multiple phase III successes, boosting Corcept and Mineralys - BioWorld MedTech
Mineralys Therapeutics’ lorundrostat shows efficacy in NEJM-published study - MSN
Lorundrostat shows promise in hypertension trial By Investing.com - Investing.com South Africa
Mineralys Therapeutics (MLYS) Shares Advance on Promising Hypert - GuruFocus
Lorundrostat shows promise in hypertension trial - Investing.com
Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM) - The Manila Times
Mineralys Therapeutics Announces Publication of Pivotal - GlobeNewswire
Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week - MSN
Mineralys therapeutics CEO Jon Congleton sells shares worth $186,802 By Investing.com - Investing.com Canada
Mineralys therapeutics CEO Jon Congleton sells shares worth $186,802 - Investing.com Australia
Mineralys Therapeutics CFO Adam Levy sells $129,684 in stock By Investing.com - Investing.com Nigeria
Mineralys Therapeutics chief medical officer sells $165,185 in stock By Investing.com - Investing.com South Africa
Mineralys Therapeutics chief medical officer sells $165,185 in stock - Investing.com Australia
Mineralys Therapeutics CFO Adam Levy sells $129,684 in stock - Investing.com
Mineralys Therapeutics Executives Sell Shares - TradingView
Institutional investors must be pleased after a 8.1% gain last week that adds to Mineralys Therapeutics, Inc.'s (NASDAQ:MLYS) one-year returns - Yahoo Finance
SEC Form DEF 14A filed by Mineralys Therapeutics Inc. - Quantisnow
SEC Form DEFA14A filed by Mineralys Therapeutics Inc. - Quantisnow
Press Release Distribution & PR Platform - ACCESS Newswire
Mineralys Therapeutics CMO Rodman sells shares worth $879,008 - Investing.com Australia
Mineralys Therapeutics CMO Rodman sells shares worth $879,008 By Investing.com - Investing.com Canada
Buy Rating Affirmed for Lorundrostat Amid Positive Trial Results and Market Potential - TipRanks
When (MLYS) Moves Investors should Listen - news.stocktradersdaily.com
Stifel maintains Buy on Mineralys stock with $45 target - Investing.com Australia
ACC25: Mineralys' uncontrolled hypertension drug aces trial - Pharmaphorum
Stifel maintains Buy on Mineralys stock with $45 target By Investing.com - Investing.com South Africa
Mineralys Therapeutics Unveils Promising Trial Results for Lorundrostat - TipRanks
Mineralys Therapeutics presents results from Phase 2 Advance-HTN trial - TipRanks
Promising Clinical Trial Results and Safety Profile of Lorundrostat Support Buy Rating for Mineralys Therapeutics - TipRanks
Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25) - The Manila Times
Mineralys Therapeutics Announces Late-Breaking Data from - GlobeNewswire
Mineralys Therapeutics Inc Stock (MLYS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Mineralys Therapeutics Inc Stock (MLYS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Rodman David Malcom | Chief Medical Officer |
Apr 14 '25 |
Option Exercise |
1.08 |
6,348 |
6,856 |
123,052 |
| Rodman David Malcom | Chief Medical Officer |
Apr 14 '25 |
Sale |
14.53 |
11,366 |
165,185 |
111,686 |
| Levy Adam Scott | CFO and Secretary |
Apr 11 '25 |
Sale |
12.06 |
10,757 |
129,684 |
215,340 |
| Congleton Jon | Chief Executive Officer |
Apr 11 '25 |
Sale |
12.19 |
15,319 |
186,803 |
862,289 |
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):